Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib (Balversa) and the importance of genetic/genomic testing in bladder cancer.
Erdafitinib is approved by the FDA for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy. Vaishampayan stresses how it is crucial that patients with bladder cancer receive genetic testing to determine their eligibility for this treatment should they progress on first-line chemotherapy.
Vaishampayan is director, Phase I Program, Rogel Cancer Center, Michigan Medicine, and professor of Internal Medicine, University of Michigan.
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.